Biotech Values

[stockbettor]

NYT article shows the following pricing for Bydureon and Victoza:

Amylin said the wholesale price of Bydureon would be $323.44 for four doses, or about $4,200 a year. That is between the roughly $3,400 for the low dose of Victoza and $5,000 for the high dose, said Mark Schoenebaum, an analyst at the ISI Group.

http://www.nytimes.com/2012/01/28/health/bydureon-a-diabetes-drug-from-amylin-wins-fda-approval.html?_r=2

At one point a few years ago I considered investing in AMLN, but it became clear to me that its management had no clue about developing a more convenient delivery system for Byetta and its other injected drugs when it not only licensed NSTK's intranasal technology but later made a $1M payment to buy the tech (if I remember correctly). NSTK at that point was morphing into an RNAI company, now known as Marina Biotech, following 2 big pharma rejections of its IN tech. NSTK/MDRNA has been one of Dew's scam favorites over the years.

It will be interesting to see how weekly Bydureon fares competing against daily Victoza. The horse needle, plus the pharmacist mixing skills needed to prepare the injection, makes me think that it will face tough sledding. However, if and when AMLN can perfect the monthly shot it is working on, I will take another look.